{"organizations": [], "uuid": "49c6f1468f3d685e2ee242a81cc26fab42d8a2ac", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dermiras-two-phase-3-trials-evalua/brief-dermiras-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints-idUSASB0C8QQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.51, "site_type": "news", "published": "2018-03-05T21:06:00.000+02:00", "replies_count": 0, "uuid": "49c6f1468f3d685e2ee242a81cc26fab42d8a2ac"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dermiras-two-phase-3-trials-evalua/brief-dermiras-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints-idUSASB0C8QQ", "ord_in_thread": 0, "title": "BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "dermira inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Dermira Inc:\n* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA INC - COMPANY EXPECTS TO DISCONTINUE PROGRAM\n* DERMIRA - NONE OF THE CO-PRIMARY ENDPOINT RESULTS WERE STATISTICALLY SIGNIFICANT\n* DERMIRA - ‍ TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS AGES 9 YRS AND OLDER ​WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA INC - ‍NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED, AND NO NEW OR UNEXPECTED EVENTS WERE OBSERVED​\n* DERMIRA - ‍CONSISTENT WITH PHASE 2A,2B STUDIES, OLUMACOSTAT GLASARETIL WAS WELL-TOLERATED WITH ADVERSE EVENTS PRIMARILY MILD OR MODERATE IN SEVERITY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T21:06:00.000+02:00", "crawled": "2018-03-06T22:16:32.009+02:00", "highlightTitle": ""}